Calton & Associates’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $284K | Sell |
5,418
-637
| -11% | -$33.7K | 0.04% | 323 |
|
|
2026
Q1 | $334K | Sell |
6,055
-4,040
| -40% | -$219K | 0.05% | 302 |
|
|
2025
Q4 | $495K | Sell |
10,095
-90
| -0.9% | -$4.2K | 0.07% | 250 |
|
|
2025
Q3 | $440K | Buy |
10,185
+2,839
| +39% | +$111K | 0.07% | 257 |
|
|
2025
Q2 | $282K | Buy |
7,346
+85
| +1% | +$3.25K | 0.05% | 298 |
|
|
2025
Q1 | $281K | Buy |
7,261
+1,102
| +18% | +$40.3K | 0.06% | 254 |
|
|
2024
Q4 | $208K | Sell |
6,159
-156
| -2% | -$5.62K | 0.09% | 184 |
|
|
2024
Q3 | $258K | Sell |
6,315
-715
| -10% | -$29.3K | 0.1% | 190 |
|
|
2024
Q2 | $271K | Sell |
7,030
-1,438
| -17% | -$60.5K | 0.14% | 141 |
|
|
2024
Q1 | $363K | Sell |
8,468
-275
| -3% | -$11.3K | 0.18% | 123 |
|
|
2023
Q4 | $324K | Buy |
+8,743
| New | +$314K | 0.13% | 154 |
|
|
2023
Q3 | – | Sell |
-7,978
| Closed | -$284K | – | 173 |
|
|
2023
Q2 | $284K | Sell |
7,978
-305
| -4% | -$10.9K | 0.13% | 150 |
|
|
2023
Q1 | $295K | Buy |
8,283
+857
| +12% | +$30K | 0.14% | 150 |
|
|
2022
Q4 | $261K | Buy |
+7,426
| New | +$247K | 0.1% | 221 |
|
|
2022
Q3 | – | Sell |
-5,762
| Closed | -$313K | – | 231 |
|
|
2022
Q2 | $313K | Sell |
5,762
-172
| -3% | -$9.49K | 0.17% | 143 |
|
|
2022
Q1 | $323K | Sell |
5,934
-167
| -3% | -$9.07K | 0.1% | 233 |
|
|
2021
Q4 | $336K | Sell |
6,101
-477
| -7% | -$24.8K | 0.09% | 238 |
|
|
2021
Q3 | $314K | Sell |
6,578
-932
| -12% | -$46.8K | 0.07% | 282 |
|
|
2021
Q2 | $374K | Buy |
7,510
+56
| +0.8% | +$2.69K | 0.07% | 249 |
|
|
2021
Q1 | $333K | Buy |
7,454
+136
| +2% | +$6.17K | 0.06% | 257 |
|
|
2020
Q4 | $337K | Sell |
7,318
-1,101
| -13% | -$50.6K | 0.06% | 237 |
|
|
2020
Q3 | $396K | Sell |
8,419
-259
| -3% | -$13K | 0.08% | 188 |
|
|
2020
Q2 | $443K | Sell |
8,678
-788
| -8% | -$40.4K | 0.1% | 164 |
|
|
2020
Q1 | $448K | Buy |
9,466
+31
| +0.3% | +$1.65K | 0.11% | 147 |
|
|
2019
Q4 | $554K | Sell |
9,435
-619
| -6% | -$34.4K | 0.11% | 162 |
|
|
2019
Q3 | $536K | Sell |
10,054
-474
| -5% | -$24.4K | 0.12% | 146 |
|
|
2019
Q2 | $527K | Sell |
10,528
-1,309
| -11% | -$65.7K | 0.15% | 117 |
|
|
2019
Q1 | $618K | Buy |
11,837
+337
| +3% | +$16.8K | 0.19% | 105 |
|
|
2018
Q4 | $549K | Buy |
11,500
+2,754
| +31% | +$136K | 0.2% | 100 |
|
|
2018
Q3 | $439K | Buy |
8,746
+1,228
| +16% | +$62.4K | 0.13% | 140 |
|
|
2018
Q2 | $391K | Buy |
7,518
+1,381
| +23% | +$69.6K | 0.11% | 146 |
|
|
2018
Q1 | $300K | Sell |
6,137
-75
| -1% | -$3.49K | 0.09% | 231 |
|
|
2017
Q4 | $300K | Buy |
+6,212
| New | +$287K | 0.08% | 244 |
|
Other funds holding GSK
JEST
Calton & Associates's GSK Position: Q2 2026 in Review
Calton & Associates reduced its GSK (GSK) stake by 11% in Q2 2026, selling an estimated $33.7K and leaving 5,418 shares worth $284K. The position accounts for 0.04% of the portfolio, ranked #323.
Calton & Associates first reported a position in GSK in Q4 2017 and has held it in 33 quarters since. The position peaked at $618K in Q1 2019. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Calton & Associates held 5,418 shares of GSK worth $284K as of Q2 2026.
- Calton & Associates sold 637 GSK shares in Q2 2026, an estimated $33.7K.
- GSK made up 0.04% of Calton & Associates's portfolio in Q2 2026, its #323 holding.
- Calton & Associates first reported a position in GSK in Q4 2017 and has held it in 33 quarters since.
- Calton & Associates's GSK position peaked at $618K in Q1 2019.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Calton & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.